10-Q quarterly report · filed Nov 5, 2026

Natera Inc (NTRA) Q3 2026 10-Q Quarterly Report

Short answer

Natera Inc (NTRA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $794M (up 34.1% year over year) with net income of −$60M.

Q3 2026 key financials · XBRL

Revenue
$794M
+34.1% YoY · +5.5% QoQ
Net income
−$60M
+31.6% YoY · +10.5% QoQ
Operating margin
-8.6%
EPS (diluted)
−$0.41
+35.9% YoY · +12.8% QoQ

Source: XBRL data from the Natera Inc (NTRA) Q3 2026 10-Q on SEC EDGAR. USD.

Natera Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $794.0M, up 34.1% YoY from $592.2M
  • Product revenue $790.0M, up 33.9%; oncology units 339,500 vs 211,000
  • Product cost margin 64.6% vs 64.9% YoY, with net loss $59.9M vs $87.5M
  • Cash $1.1B; operating cash flow $138.9M, down from $141.4M; capital spending $124.2M
  • Outlook: continued net losses, heavy R&D investment, potential need for additional equity or debt financing

Risk Factors

  • No material changes reported from the December 31, 2025 Form 10-K
  • Carried-forward business risk: disclosed 10-K risks could materially adversely affect operations and prospects
  • Market risk: adverse developments could reduce common-stock price and investor returns
  • Disclosure risk: additional unknown or currently immaterial risks could materially harm results

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.